pindolol has been researched along with Depression in 21 studies
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A case is reported of a 34-year-old lady with a 2-year history of resistant depression who responded to pindolol augmentation of sertraline." | 7.70 | Pindolol augmentation of sertraline in resistant depression and its effect on sleep. ( Bell, C; Nutt, DJ; Wilson, S, 1998) |
| " After a 1-week placebo run-in period, 72 patients received fluvoxamine 300 mg/day in combination with placebo or pindolol 7." | 6.69 | Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. ( Franchini, L; Gasperini, M; Lucca, A; Perez, J; Smeraldi, E; Zanardi, R, 1998) |
| "Of 132 eligible patients with major depression, 111 were randomly assigned to treatment with fluoxetine (20 mg daily) and either placebo or pindolol (7." | 5.08 | Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. ( Alvarez, E; Artigas, F; Faries, D; Gilaberte, I; Pérez, V, 1997) |
| "The effect of inositol as an antidepressant was previously demonstrated in both animal models of depression-like behavior and in clinical trials." | 3.71 | The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors. ( Belmaker, RH; Bourin, M; Clenet, F; Einat, H; Shaldubina, A, 2001) |
| "A case is reported of a 34-year-old lady with a 2-year history of resistant depression who responded to pindolol augmentation of sertraline." | 3.70 | Pindolol augmentation of sertraline in resistant depression and its effect on sleep. ( Bell, C; Nutt, DJ; Wilson, S, 1998) |
| "Pindolol was initially used due to its ability to block 5-HT1A receptor-mediated responses and to enhance the neurochemical effects of SSRIs." | 2.43 | Pindolol augmentation of antidepressant response. ( Adell, A; Artigas, F; Celada, P, 2006) |
| " In patients who have experienced only partial treatment results, the clinician should first consider optimizing antidepressant dosage or lengthening therapy." | 2.40 | Practical management of treatment-resistant depression. ( Cadieux, RJ, 1998) |
| " Using drugs together may increase the risk of adverse effects, through potentiation of existing adverse effects or alterations in plasma concentrations of the drug." | 2.40 | Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression. ( Schweitzer, I; Tuckwell, V, 1998) |
| " However, the optimal dosing schedule of pindolol remains controversial." | 1.33 | A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol. ( Dauphin, A; Gruwez, B; Tod, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 11 (52.38) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laver, B | 1 |
| Diwan, M | 1 |
| Nobrega, JN | 1 |
| Hamani, C | 1 |
| Nautiyal, KM | 1 |
| Tritschler, L | 1 |
| Ahmari, SE | 1 |
| David, DJ | 1 |
| Gardier, AM | 1 |
| Hen, R | 1 |
| Jiang, XZ | 1 |
| Li, YF | 1 |
| Zhang, YZ | 1 |
| Chen, HX | 1 |
| Li, J | 1 |
| Wang, NP | 1 |
| Portella, MJ | 1 |
| de Diego-Adeliño, J | 1 |
| Puigdemont, D | 1 |
| Pérez-Egea, R | 1 |
| Alvarez, E | 2 |
| Artigas, F | 3 |
| Pérez, V | 2 |
| Gruwez, B | 1 |
| Dauphin, A | 1 |
| Tod, M | 1 |
| Adell, A | 1 |
| Celada, P | 1 |
| Geretsegger, C | 1 |
| Bitterlich, W | 1 |
| Stelzig, R | 1 |
| Stuppaeck, C | 1 |
| Bondy, B | 1 |
| Aichhorn, W | 1 |
| Tejani-Butt, SM | 1 |
| Paré, WP | 1 |
| Yang, J | 1 |
| Blier, P | 1 |
| Bergeron, R | 1 |
| Gilaberte, I | 1 |
| Faries, D | 1 |
| Bourin, M | 2 |
| Redrobe, JP | 1 |
| Baker, GB | 1 |
| Bell, C | 1 |
| Wilson, S | 1 |
| Nutt, DJ | 1 |
| Gurguis, GN | 1 |
| Yonkers, KA | 1 |
| Blakeley, JE | 1 |
| Phan, SP | 1 |
| Williams, A | 1 |
| Rush, AJ | 1 |
| Cryan, JF | 1 |
| McGrath, C | 1 |
| Leonard, BE | 1 |
| Norman, TR | 1 |
| Mundo, E | 1 |
| Guglielmo, E | 1 |
| Bellodi, L | 1 |
| Cadieux, RJ | 1 |
| Zanardi, R | 1 |
| Franchini, L | 1 |
| Gasperini, M | 1 |
| Lucca, A | 1 |
| Smeraldi, E | 1 |
| Perez, J | 1 |
| Schweitzer, I | 1 |
| Tuckwell, V | 1 |
| Einat, H | 1 |
| Clenet, F | 1 |
| Shaldubina, A | 1 |
| Belmaker, RH | 1 |
| Kohn, R | 1 |
| Koella, WP | 1 |
5 reviews available for pindolol and Depression
| Article | Year |
|---|---|
Pindolol augmentation of antidepressant response.
Topics: Brain; Depression; Humans; Pindolol; Serotonin 5-HT1 Receptor Antagonists; Serotonin Antagonists; Tr | 2006 |
Practical management of treatment-resistant depression.
Topics: Antidepressive Agents; Buspirone; Depression; Drug Resistance; Drug Therapy, Combination; Humans; Li | 1998 |
Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Drug Resistance; Drug Therapy, | 1998 |
Beta-blockers an important cause of depression: a medical myth without evidence.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents; Antihypertensive Agents; Controlled Clinical Tri | 2001 |
CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action.
Topics: Adrenergic beta-Antagonists; Amphetamine; Animals; Anxiety; Blood-Brain Barrier; Central Nervous Sys | 1985 |
5 trials available for pindolol and Depression
| Article | Year |
|---|---|
Pindolol augmentation enhances response outcomes in first depressive episodes.
Topics: Adolescent; Adult; Antidepressive Agents; Depression; Double-Blind Method; Drug Therapy, Combination | 2009 |
Paroxetine with pindolol augmentation: a double-blind, randomized, placebo-controlled study in depressed in-patients.
Topics: Adult; Depression; Double-Blind Method; Drug Evaluation; Drug Synergism; Female; Humans; Inpatients; | 2008 |
Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Drug Therapy, Comb | 1997 |
Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Drug Therapy, Comb | 1998 |
Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; | 1998 |
11 other studies available for pindolol and Depression
| Article | Year |
|---|---|
Augmentative therapies do not potentiate the antidepressant-like effects of deep brain stimulation in rats.
Topics: Animals; Behavior, Animal; Buspirone; Deep Brain Stimulation; Depression; Dopamine Antagonists; Gyru | 2014 |
A Lack of Serotonin 1B Autoreceptors Results in Decreased Anxiety and Depression-Related Behaviors.
Topics: Animals; Animals, Newborn; Anxiety; Autoreceptors; Depression; Disease Models, Animal; Exploratory B | 2016 |
[5-HT1A/1B receptors, alpha2-adrenoceptors and the post-receptor adenylate cyclase activation in the mice brain are involved in the antidepressant-like action of agmatine].
Topics: Adenylyl Cyclases; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Agmatine; Animals; Ant | 2008 |
A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol.
Topics: Algorithms; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Depression; Dose-Res | 2005 |
Effect of repeated novel stressors on depressive behavior and brain norepinephrine receptor system in Sprague-Dawley and Wistar Kyoto (WKY) rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Body Weight; Brain; Carrier Prot | 1994 |
Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings.
Topics: Adrenergic beta-Antagonists; Adult; Buspirone; Depression; Drug Resistance; Drug Therapy, Combinatio | 1996 |
Pindolol does not act only on 5-HT1A receptors in augmenting antidepressant activity in the mouse forced swimming test.
Topics: Adrenergic beta-Antagonists; Animals; Antidepressive Agents; Depression; Dose-Response Relationship, | 1998 |
Pindolol augmentation of sertraline in resistant depression and its effect on sleep.
Topics: 1-Naphthylamine; Adrenergic beta-Antagonists; Adult; Antidepressive Agents; Brain; Depression; Drug | 1998 |
Adrenergic receptors in premenstrual dysphoric disorder. II. Neutrophil beta2-adrenergic receptors: Gs protein coupling, phase of menstrual cycle and prediction of luteal phase symptom severity.
Topics: Adult; Anxiety; Case-Control Studies; Depression; Female; Follicular Phase; GTP-Binding Proteins; Hu | 1998 |
Combining pindolol and paroxetine in an animal model of chronic antidepressant action--can early onset of action be detected?
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic beta-Antagonists; Animals; Antidepressive Agents; | 1998 |
The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors.
Topics: Animals; Antidepressive Agents; Benzylamines; Depression; Disease Models, Animal; Drug Interactions; | 2001 |